TAT 2018 - Targeted Anticancer Therapies

Oncology Meeting Resources

05 Mar - 07 Mar 2018, Paris, France

TAT 2018

TAT 2018 - Targeted Anticancer Therapies focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. Presentations and webcasts from the TAT 2018 - Targeted Anticancer Therapies are available here to ESMO members.

Watch ESMO video reports from experts:

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme  | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...-acute-lymphocytic-leukemia-Path-to-the-cure

Date: 05 Mar 2018
Presenter: Elias Jabbour
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...erSaVax-the-road-so-far-and-the-future-ahead

The vascular endothelial growth factor (VEGF) plays a central role in angiogenesis and immunosuppressive cascades inherent to tumor development. Success of drugs targeting this growth factor and their...

Date: 05 Mar 2018
Presenter: Mónica Bequet-Romero
Resources: Abstract, Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...-immune-responses-against-established-tumors

Virus-based vaccines and appropriate costimulation enhance potent antigen-specific T cell immunity against cancer. In the present study we exploit both innate and adaptive immune responses triggered...

Date: 05 Mar 2018
Presenter: Jose Medina
Resources: Abstract, Presentation
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...ellular-carcinoma-in-Phase-I-clinical-trials

In Asia, chronic hepatitis B and C virus infections (CHVI) are major risk factors for liver fibrosis and hepatocellular carcinoma (HCC). Patients with advanced HCC have limited effective therapeutic...

Date: 05 Mar 2018
Presenter: Takafumi Koyama
Resources: Abstract
Topics: Hepatobiliary Cancers, Cancer in Special Situations

https://oncologypro.esmo.org/Meeting-Resour...rowth-and-survival-of-rhabdomyosarcoma-cells

The poly(ADP-ribose) polymerase inhibitors (PARPi) are used in a wide range of human solid tumours but a limited evidence is reported in rhabdomyosarcoma (RMS), the most frequent soft-tissue sarcoma in children and adolescents.

Date: 05 Mar 2018
Presenter: Francesca Megiorni
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ar-Sphingosine-Kinase-1-SphK1-in-lung-cancer

Sphingosine kinases (SphKs) are enzymes catalyzing the formation of a bioactive lipid messenger, sphingosine-1-phosphate (S1P) through phosphorylation of sphingosine.

Date: 05 Mar 2018
Presenter: Fabiana Napolitano
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...bination-therapy-in-MYC-driven-neuroblastoma

Despite intensive multimodal therapy, more than 50% of children with high-risk neuroblastoma eventually succumb to the disease. MYC signaling is a predominant driver of high-risk neuroblastoma, caused...

Date: 05 Mar 2018
Presenter: Katharina Firle
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...tumor-and-metastasis-in-breast-cancer-models

Biomarkers CD44 and CD24 are routinely used to identify breast cancer stem cells (BCSCs). BCSCs are chemotherapy resistant and bear high tumorigenesis and metastatic capabilities.

Date: 05 Mar 2018
Presenter: Sumanta Goswami
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...eted-Therapies-In-Patients-With-Solid-Tumors

Most targeted therapies in cancer have reached approval based on clinical studies performed in unselected patients. Small subsets of patients present exceptional responses (ER), which could be driven...

Date: 05 Mar 2018
Presenter: Olivia Le Saux
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...er-Stem-Cells-to-Carbon-Ion-Beam-Irradiation

Increasing evidence shows that microRNAs (miRNA), a family of small non-coding RNAs, play a pivotal role in regulating mRNA translation. Recently, some miRNAs have been shown to be involved in regulating cancer stem cell (CSC) properties.

Date: 05 Mar 2018
Presenter: Sei Sai
Resources: Abstract